Clinical Trials Logo

Cardiomyopathies clinical trials

View clinical trials related to Cardiomyopathies.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06434415 Active, not recruiting - Clinical trials for Hypertrophic Cardiomyopathy

Prognostic Value of Coronary Angiography-Derived Index of Microcirculatory Resistance in Hypertrophic Cardiomyopathy Patients

Start date: January 1, 2017
Phase:
Study type: Observational

Coronary microvascular dysfunction (CMD) is among pathophysiological states of significance in hypertrophic cardiomyopathy (HCM). The index of microcirculatory resistance (IMR) has been recognized as an indicator of CMD and considered of important prognostic value in various conditions. The angiography-derived index of microcirculatory resistance (angio-IMR) is a novel guidewire-free method to assess IMR and proved to have favourable correlation with it. This study was designed to assess prognostic impact of CMD in HCM patients, using angio-IMR as a novel non-invasive assessment tool.

NCT ID: NCT06372457 Active, not recruiting - Clinical trials for Hypertrophic Cardiomyopathy (HCM)

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

COLLIGO-HCM
Start date: December 1, 2023
Phase:
Study type: Observational

COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.

NCT ID: NCT06321523 Active, not recruiting - Clinical trials for Transthyretin Amyloid Cardiomyopathy

A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Start date: March 19, 2024
Phase:
Study type: Observational

The purpose of this clinical trial is to learn about the effects of the study medicine (called Tafamidis 61milligrams (mg)) for the potential treatment of Transthyretin amyloid cardiomyopathy (ATTR-CM). This study is seeking participants who were prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once. We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective.

NCT ID: NCT06257485 Active, not recruiting - Clinical trials for Transthyretin Amyloid Cardiomyopathy

Bronx Transthyretin Amyloid Cardiomyopathy Database

Start date: September 23, 2023
Phase:
Study type: Observational

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PYP) Single Photon Emission Computed Tomography (SPECT) between 2014 and 2023 at Montefiore-Einstein in the Bronx. The patient population is racially and ethnically diverse and with a high proportion of females. Demographic, clinical (e.g. comorbidities), laboratory, echocardiographic, hospitalization, and mortality data were collected for each patient.

NCT ID: NCT06211595 Active, not recruiting - Clinical trials for Obstructive Hypertrophic Cardiomyopathy

Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy

Start date: October 13, 2022
Phase: N/A
Study type: Interventional

This is a prospective, single-center, single-arm clinical study. All patients were diagnosed with obstructive hypertrophic cardiomyopathy, and only subjects who met the instrument indications of this study were treated. After signing an informed consent form, subjects are enrolled and treated with the DragonFire Transcatheter Myocardial Ablation System. All subjects receive clinical follow-up immediately after the procedure, before discharge, 30 days after the procedure, 6 months after the procedure, and 12 months after the procedure.

NCT ID: NCT06073587 Active, not recruiting - Clinical trials for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

The CARDIO-TTRansform Scintigraphy Sub-study

Start date: April 4, 2023
Phase:
Study type: Observational

The purpose of this study is to examine the changes in amyloid myocardial burden in a subset of the population participating in the ION682884-CS2 (NCT04136171) study, up to 150 participants, after treatment with eplontersen or placebo based on scintigraphy scans performed at Week 140 using the Perugini grade score method.

NCT ID: NCT06073574 Active, not recruiting - Clinical trials for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

Start date: March 31, 2021
Phase:
Study type: Observational

The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).

NCT ID: NCT06031519 Active, not recruiting - Arrhythmia Clinical Trials

Impact of Liwen Procedure in Obstructive Hypertrophic Cardiomyopathy on Arrhythmias

Start date: August 22, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the occurrence of various arrhythmias ( tachyarrhythmia and bradyarrhythmia ) during or after Percutaneous Intramyocardial Septal Radiofrequency Ablation. The main questions it aims to answer are: - To investigate the occurrence of various arrhythmias ( tachyarrhythmia and bradyarrhythmia ) during procedure and its relationship with clinical characteristics and procedural parameters - To analyze the changes of 12-lead electrocardiogram and 24-hour dynamic electrocardiogram before and after Percutaneous Intramyocardial Septal Radiofrequency Ablation and their relationships with clinical characteristics and procedural parameters

NCT ID: NCT06008340 Active, not recruiting - Clinical trials for Pacing-Induced Cardiomyopathy

Effect of Right Ventricle Lead Position on The Psychological Aspects of Patients With A Dual Chamber Pacemaker

Start date: August 1, 2022
Phase:
Study type: Observational [Patient Registry]

The purpose of the current study was to determine the factors associated with increased levels of anxiety and depression both before and after pacemaker implantation and examine if changes in these symptoms occur during the first postoperative year.

NCT ID: NCT06003478 Active, not recruiting - Clinical trials for Hypertrophic Obstructive Cardiomyopathy

The Safety and Influencing Factors of Liwen Procedure in The Treatment of Hypertrophic Cardiomyopathy

Start date: July 21, 2023
Phase:
Study type: Observational

Liwen procedure is generally safe and effective in treating hypertrophic cardiomyopathy, but a small proportion of patients have complications after the operation. The goal of this observational study is to explore the incidence of postoperative complications of the Liwen procedure in hypertrophic cardiomyopathy patients underwent Liwen procedure in Xijing Hospital. The main question it aims to answer are: - What is the incidence of complications in HCM patients underwent Liwen Procedure during postoperative hospitalization and a short-term follow-up period? - What is the relevant factors of complications in HCM patients who underwent Liwen Procedure during postoperative hospitalization and short-term follow-up period? Can the complications of surgical patients during postoperative hospitalization be predicted? Participants have been evaluated using a variety of medical examinations before they underwent Liwen Procedure. Variants collected from medical examination and case history were used to analyze the association with each postoperative complication.